Bayer may hive off another unit as it doubles down on pharma, consumer health

Carly Helfand

Turns out it may not be just 's plastics business that's on its way out the door. The company is reportedly exploring a sale of its diabetes device business as it rides 's slim- wave.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS